Abstract
Castration-resistant prostate cancer is a complex disease, treatment requires a multidisciplinary approach and use of various modalities, ideally in their combination. Symptomatic bone metastases can be also effectively managed by administration of systemic beta emitters (strontium-89 and samarium-153) or localized external beam radiotherapy.
Most recently, an alpha emitter radium-223 has been introduced with a positive impact on increased overall survival of patients with bone metastases. Safety profile of radium-223 is very favorable with a minimal risk of serious hematologic complications.
Six intravenous injections are administered on an outpatient basis with a positive effect on the quality of life and with minimal restrictions with regard to the patient's and his family's daily life.